Curis, Inc. Announces First Mesothelioma Patient Has Been Enrolled and Dosed in the Phase I Study of CA-170
January 24, 2019 at 07:00 am EST
Share
Curis, Inc. announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression. Over 90% of mesothelioma cells express VISTA. The company had previously announced its expectation to begin enrollment of mesothelioma patients in a dedicated cohort within the existing Phase 1 study. CA-170 is the only anti-VISTA therapeutic currently being studied in a clinical trial. CA-170 has demonstrated favorable safety and tolerability, as well as preliminary anti-tumor activity in patients across multiple tumor types. The Phase I study is the first clinical trial of CA-170 to specifically target a patient population characterized by high levels of VISTA expression.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
CURIS, INC. 
